直接口服抗凝药与脱发:上市后数据的支持
基于VigiBase数据库截至2018年5月2日的报告,分析DOACs相关脱发报告,共检索到1316份,多数涉及利伐沙班(58.8%),80%为女性,中位发病时间28天,54.3%因果关系评为可能。结论提示DOACs与脱发可能存在关联,需进一步观察性研究证实。
要点
- DOACs相关脱发报告以利伐沙班为主,女性占80%。
- 中位发病时间28天,因果关系多评为可能。
- 需进一步观察性研究确认关联。
核心结论
- DOACs给药与脱发之间可能存在关联,但需进一步观察性研究确认。
研究设计与样本
- 基于VigiBase数据库的回顾性描述性分析,检索截至2018年5月2日的DOACs相关脱发报告,共1316份。
主要发现
- 1316份报告中,58.8%涉及利伐沙班。
- 80%的报告与女性相关,其中23.1%为65岁及以上女性。
- 中位发病时间为28天,四分位距63天。
- 54.3%的报告因果关系评估为可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Little is known about the administration of direct-acting oral anticoagulants (DOACs) and the occurrence of alopecia. Our aim was to analyse the reports of alopecia following DOAC administration received until 2 May 2018 from VigiBase, the World Health Organization database. A descriptive analysis of age, sex, seriousness and dechallenge/rechallenge outcome was carried out. For each report, the time-to-onset was evaluated and the causality was assessed by using Naranjo algorithm. Overall, 1316 reports were retrieved, most concerning rivaroxaban (58.8%); 80% of the reports were related to females, in particular to those aged ≥65 years (23.1%). The median value of the time-to-onset was 28 days, with an interquartile range of 63 days. In 54.3% of the reports the causality was assessed as possible. In conclusion, a possible association could exist between DOACs administration and alopecia, but further observational studies are needed to confirm these findings.
引用
- Bonaldo G, Vaccheri A, Motola D, et al. Direct-acting oral anticoagulants and alopecia: The valuable support of postmarketing data. Br J Clin Pharmacol. 2020. PMID: 31950530. doi:10.1111/bcp.14221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。